The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis
出版年份 2017 全文链接
标题
The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis
作者
关键词
-
出版物
Expert Review of Clinical Immunology
Volume 14, Issue 1, Pages 1-19
出版商
Informa UK Limited
发表日期
2017-11-07
DOI
10.1080/1744666x.2018.1401468
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders
- (2017) Anna Balato et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Certolizumab pegol for the treatment of psoriasis
- (2017) A. Campanati et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis
- (2017) Zenas Z. N. Yiu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
- (2017) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3
- (2017) C.L. Leonardi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials
- (2017) L. Guenther et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression
- (2017) J. Koo et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis
- (2017) Hema N. Viswanathan et al. VALUE IN HEALTH
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- FRI0446 Treatment with Tildrakizumab, An Anti-IL-23P19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis
- (2016) D. Thaçi et al. ANNALS OF THE RHEUMATIC DISEASES
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
- (2016) Vibeke Strand et al. ANNALS OF THE RHEUMATIC DISEASES
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period
- (2016) M. Megna et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry
- (2016) Pierre Jungo et al. DERMATOLOGY
- Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity
- (2016) Andrea Chiricozzi et al. Expert Review of Clinical Immunology
- Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis
- (2016) Neil J. Korman et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis
- (2016) Philip J. Mease et al. JOURNAL OF RHEUMATOLOGY
- Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent
- (2016) Paul S. Yamauchi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
- (2016) Alexandra B. Kimball et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States
- (2016) Melissa J. Danesh et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
- (2016) Bruce E. Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A systematic review of worldwide epidemiology of psoriasis
- (2016) I.M. Michalek et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis
- (2016) April W. Armstrong et al. JAMA Dermatology
- EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis
- (2016) A. Simon Pickard et al. JOURNAL OF MEDICAL ECONOMICS
- Genetic polymorphisms of IL-17A, IL-17F, TLR4 and miR-146a in association with the risk of pulmonary tuberculosis
- (2016) Min Wang et al. Scientific Reports
- Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
- (2015) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
- (2015) C. Paul et al. BRITISH JOURNAL OF DERMATOLOGY
- Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
- (2015) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
- (2015) Michele W L Teng et al. NATURE MEDICINE
- Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis
- (2014) Hema N. Viswanathan et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Cell‐, Platelet‐, and Monocyte/Macrophage‐Derived Microparticles are Elevated in Psoriasis Beyond Cardiometabolic Risk Factors
- (2014) Junko Takeshita et al. Journal of the American Heart Association
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
- (2013) P J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory
- (2013) K.B. Gordon et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis and smoking: a systematic review and meta-analysis
- (2013) A.W. Armstrong et al. BRITISH JOURNAL OF DERMATOLOGY
- Cardiovascular aspects of psoriasis: an updated review
- (2013) Aldona Pietrzak et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway
- (2013) A. Balato et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
- (2013) D. Gladman et al. ARTHRITIS CARE & RESEARCH
- Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
- (2012) Vibeke Strand et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting
- (2012) Joy Wan ARCHIVES OF DERMATOLOGY
- Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis
- (2012) Nehal N. Mehta et al. ATHEROSCLEROSIS
- Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
- (2012) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity
- (2012) Donald M. Bushnell et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity
- (2012) Mona L. Martin et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study
- (2012) K. Papp et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Human genetic susceptibility toCandidainfections
- (2012) Theo S. Plantinga et al. MEDICAL MYCOLOGY
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
- (2011) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity
- (2011) Wolf-Henning Boehncke et al. EXPERIMENTAL DERMATOLOGY
- Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Caitriona Ryan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis
- (2011) April W. Armstrong et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk
- (2011) Edi Kaminska et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2011) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials
- (2011) L. Guenther et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone
- (2011) C. F. Rosen et al. RHEUMATOLOGY
- Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.
- (2010) K Abuabara et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis: depression, anxiety, smoking, and drinking habits
- (2010) Jennifer Hayes et al. Dermatologic Therapy
- Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2
- (2010) Kristian Reich et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
- (2010) Batya B. Davidovici et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
- (2010) Richard G. Langley et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial
- (2010) JC Prinz et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature
- (2010) V Bronsard et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validity of the work productivity and activity impairment questionnaire - general health version in patients with rheumatoid arthritis
- (2010) Wei Zhang et al. ARTHRITIS RESEARCH & THERAPY
- Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
- (2009) M. Lebwohl et al. BRITISH JOURNAL OF DERMATOLOGY
- Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
- (2009) N. N. Mehta et al. EUROPEAN HEART JOURNAL
- Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study
- (2009) E Daudén et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
- (2008) P J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Psoriasis Independently Associated With Hyperleptinemia Contributing to Metabolic Syndrome
- (2008) Yi-Ju Chen et al. ARCHIVES OF DERMATOLOGY
- A PEGylated Fab′ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease
- (2008) Tim Bourne et al. BIODRUGS
- Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension
- (2008) P.C.M. van de Kerkhof et al. BRITISH JOURNAL OF DERMATOLOGY
- Serum leptin levels, skin leptin and leptin receptor expression in psoriasis
- (2008) A.A. Çerman et al. BRITISH JOURNAL OF DERMATOLOGY
- Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach
- (2008) F. Späh BRITISH JOURNAL OF DERMATOLOGY
- Adipocytokines and the Metabolic Complications of Obesity
- (2008) Neda Rasouli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents
- (2008) Sean D. Doherty et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004
- (2008) Shanu Kohli Kurd et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started